Drug intelligence / Profile preview

naoliqing wan

Development stage: Unknown
Lead developer: Shandong Wohua Pharmaceutical
Administration: Oral

Overview

Naoliqing Wan is a traditional Chinese medicine (TCM) formulation manufactured by Shandong Wohua Pharmaceutical. It is primarily indicated for the treatment of symptoms associated with hypertension and cerebrovascular disorders, such as dizziness, headache, and tinnitus. In the context of TCM theory, the pill is used to "calm the liver and subdue yang" (ping gan qian yang), addressing conditions characterized by liver-yang hyperactivity. The formulation typically consists of a complex mixture of mineral and herbal ingredients, including magnetite, hematite, achyranthes root, and scutellaria. It is an approved pharmaceutical product in China and is administered orally in pill form.

Brand names: Naoliqing Wan
Other names: 脑立清丸Naoliqing Pill

Beyond the preview

Go deeper on naoliqing wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naoliqing wan.

Explore the full profile